Considering that the pRB signaling is inhibited by kinase activities of the CDK4/CDK6 and Cyclin D complex, the inactivation of CDK4/6 could be a novel anti-glioblastoma treatment option for GBM patients with aberrant expression of pRB [30]. Here, CDK4 is linked to glioblastoma.